174 related articles for article (PubMed ID: 23982344)
21. Effects of gold complexes on the assembly behavior of human islet amyloid polypeptide.
He L; Zhu D; Zhao C; Jia X; Wang X; Du W
J Inorg Biochem; 2015 Nov; 152():114-22. PubMed ID: 26383119
[TBL] [Abstract][Full Text] [Related]
22. Zinc, copper, and carnosine attenuate neurotoxicity of prion fragment PrP106-126.
Kawahara M; Koyama H; Nagata T; Sadakane Y
Metallomics; 2011 Jul; 3(7):726-34. PubMed ID: 21442127
[TBL] [Abstract][Full Text] [Related]
23. Methionine oxidation of amyloid peptides by peroxovanadium complexes: inhibition of fibril formation through a distinct mechanism.
He L; Wang X; Zhu D; Zhao C; Du W
Metallomics; 2015 Dec; 7(12):1562-72. PubMed ID: 26444976
[TBL] [Abstract][Full Text] [Related]
24. Hetero-oligomeric Amyloid Assembly and Mechanism: Prion Fragment PrP(106-126) Catalyzes the Islet Amyloid Polypeptide β-Hairpin.
Ilitchev AI; Giammona MJ; Olivas C; Claud SL; Lazar Cantrell KL; Wu C; Buratto SK; Bowers MT
J Am Chem Soc; 2018 Aug; 140(30):9685-9695. PubMed ID: 29989407
[TBL] [Abstract][Full Text] [Related]
25. PrP106-126 peptide disrupts lipid membranes: influence of C-terminal amidation.
Zheng W; Wang L; Hong Y; Sha Y
Biochem Biophys Res Commun; 2009 Feb; 379(2):298-303. PubMed ID: 19103159
[TBL] [Abstract][Full Text] [Related]
26. Molecular interaction of TPPP with PrP antagonized the CytoPrP-induced disruption of microtubule structures and cytotoxicity.
Zhou RM; Jing YY; Guo Y; Gao C; Zhang BY; Chen C; Shi Q; Tian C; Wang ZY; Gong HS; Han J; Xu BL; Dong XP
PLoS One; 2011; 6(8):e23079. PubMed ID: 21857997
[TBL] [Abstract][Full Text] [Related]
27. Calnexin inhibits thermal aggregation and neurotoxicity of prion protein.
Wang W; Chen R; Luo K; Wu D; Huang L; Huang T; Xiao G
J Cell Biochem; 2010 Oct; 111(2):343-9. PubMed ID: 20506117
[TBL] [Abstract][Full Text] [Related]
28. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.
Tagliavini F; Forloni G; Colombo L; Rossi G; Girola L; Canciani B; Angeretti N; Giampaolo L; Peressini E; Awan T; De Gioia L; Ragg E; Bugiani O; Salmona M
J Mol Biol; 2000 Jul; 300(5):1309-22. PubMed ID: 10903871
[TBL] [Abstract][Full Text] [Related]
29. Interaction of the human prion protein PrP106-126 with metal complexes: potential therapeutic agents against prion disease.
Wang Y; Xu J; Wang L; Zhang B; Du W
Chemistry; 2010 Dec; 16(45):13339-42. PubMed ID: 21031373
[No Abstract] [Full Text] [Related]
30. Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126.
Stewart LR; White AR; Jobling MF; Needham BE; Maher F; Thyer J; Beyreuther K; Masters CL; Collins SJ; Cappai R
J Neurosci Res; 2001 Sep; 65(6):565-72. PubMed ID: 11550224
[TBL] [Abstract][Full Text] [Related]
31. Specific binding modes of Cu(I) and Ag(I) with neurotoxic domain of the human prion protein.
Valensin D; Padula EM; Hecel A; Luczkowski M; Kozlowski H
J Inorg Biochem; 2016 Feb; 155():26-35. PubMed ID: 26606290
[TBL] [Abstract][Full Text] [Related]
32. Spectroscopic and electronic structure studies of copper(II) binding to His111 in the human prion protein fragment 106-115: evaluating the role of protons and methionine residues.
Rivillas-Acevedo L; Grande-Aztatzi R; Lomelí I; García JE; Barrios E; Teloxa S; Vela A; Quintanar L
Inorg Chem; 2011 Mar; 50(5):1956-72. PubMed ID: 21261254
[TBL] [Abstract][Full Text] [Related]
33. Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.
Ning L; Pan D; Zhang Y; Wang S; Liu H; Yao X
PLoS One; 2015; 10(5):e0125899. PubMed ID: 25993001
[TBL] [Abstract][Full Text] [Related]
34. Polymerization of human prion peptide HuPrP 106-126 to amyloid in nucleic acid solution.
Nandi PK
Arch Virol; 1998; 143(7):1251-63. PubMed ID: 9722872
[TBL] [Abstract][Full Text] [Related]
35. Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic.
Florio T; Paludi D; Villa V; Principe DR; Corsaro A; Millo E; Damonte G; D'Arrigo C; Russo C; Schettini G; Aceto A
J Neurochem; 2003 Apr; 85(1):62-72. PubMed ID: 12641727
[TBL] [Abstract][Full Text] [Related]
36. Interaction between 14-3-3β and PrP influences the dimerization of 14-3-3 and fibrillization of PrP106-126.
Han J; Song QQ; Sun P; Zhang J; Wang X; Song J; Li GQ; Liu YH; Mei GY; Shi Q; Tian C; Chen C; Gao C; Zhao B; Dong XP
Int J Biochem Cell Biol; 2014 Feb; 47():20-8. PubMed ID: 24269782
[TBL] [Abstract][Full Text] [Related]
37. Synthetic miniprion PrP106.
Bonetto V; Massignan T; Chiesa R; Morbin M; Mazzoleni G; Diomede L; Angeretti N; Colombo L; Forloni G; Tagliavini F; Salmona M
J Biol Chem; 2002 Aug; 277(35):31327-34. PubMed ID: 12058037
[TBL] [Abstract][Full Text] [Related]
38. Altered toxicity of the prion protein peptide PrP106-126 carrying the Ala(117)-->Val mutation.
Brown DR
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):785-91. PubMed ID: 10698707
[TBL] [Abstract][Full Text] [Related]
39. Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231).
Martins SM; Frosoni DJ; Martinez AM; De Felice FG; Ferreira ST
J Biol Chem; 2006 Sep; 281(36):26121-8. PubMed ID: 16844683
[TBL] [Abstract][Full Text] [Related]
40. Amidation and structure relaxation abolish the neurotoxicity of the prion peptide PrP106-126 in vivo and in vitro.
Bergström AL; Cordes H; Zsurger N; Heegaard PM; Laursen H; Chabry J
J Biol Chem; 2005 Jun; 280(24):23114-21. PubMed ID: 15824101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
